Erosive Esophagitis

·MeSH: Gastroesophageal Reflux

18 drugs in development·11 companies·4 clinical trials

Drug Pipeline by Phase

Approved(14)

Drug	Company
dexlansoprazole	Mylan II B.V. (MYL)
esomeprazole magnesium	Mylan II B.V. (MYL)
esomeprazole magnesium	SUNSET ISLAND GROUP (SUN)
esomeprazole magnesium	EXELIXIS, INC. (EXEL)
esomeprazole magnesium	LANNETT CO INC (LCI)
famotidine	Mersana Therapeutics, Inc. (MRSN)
famotidine	ENGENE HOLDINGS INC. (ENGN)
famotidine	Seagen Inc. (SGEN)
famotidine	Miromatrix Medical Inc. (MIRO)
famotidine	SUNSET ISLAND GROUP (SUN)
famotidine	Avita Medical Inc. (RCEL)
nexium	ASTRAZENECA PLC (AZN)
pantoprazole	EXELIXIS, INC. (EXEL)
pantoprazole	SUNSET ISLAND GROUP (SUN)

Phase 3(4)

Drug	Company
Vonoprazan	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA)	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA) - as-needed regimen	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA) - EoE	Phathom Pharmaceuticals, Inc. (PHAT)

BioSniper tracks 18 drugs in development for Erosive Esophagitis across 11 companies.

There are 4 clinical trials targeting Erosive Esophagitis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.